Published July 28, 2018 | Version v1
Journal article Open

EXTRAINTESTINAL MANIFESTATIONS OF CROHN'S DISEASE.

Authors/Creators

  • 1. Medical Faculty – University of Tetovo, Republic of North Macedonia
  • 2. Department of Surgery, University of Medicine, Tirana, Albania

Description

Introduction: Extraintestinal manifestations of Crohn's disease are common and result from the autoimmune inflammatory pathology extending into organs outside the gastrointestinal system, such as the hepatobiliary tree, pancreas, skin, eyes, and oral cavity. 

Case report: A 58-year-old male patient was referred to our Department due to severe abdominal pain. The patient's medical history shows that he has suffered from Crohn's disease for fifteen years. He had a resection of the terminal ileum in 2009. After that, he was treated because of constriction at the major duodenal papilla, and a bile duct prosthesis was inserted. For five years, the remission of the disease was maintained with azathioprine.

Three months after stopping the therapy with azathioprine, he began to complain of upper abdominal pain in the back. After admission to our Department, an abdominal CT with contrast revealed changes in the pancreas. The leukocyte count was 30 × 10^9/L, the CRP level was 98 mg/L, and severe hypoalbuminemia was present at 22 g/L. The patient was transferred to the intensive care unit for further treatment. 

Conclusion: Crohn's disease is a systemic disease that may be associated with many extra-intestinal manifestations. For these reasons, it is crucial to understand the complexity of this disease, which necessitates a comprehensive approach to treating autoimmune disorders.

Files

Haxhirexha D. F et al. Extraintestinal Manifestations of Crohn’s Disease .pdf

Files (624.6 kB)

Additional details

References

  • Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-41
  • Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678
  • Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9: 1092-107
  • Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1598-1619
  • Navaneethan U, G K Venkatesh P, Lashner BA, Lopez R, Kiran RP, et al. Severity of primary sclerosing cholangitis and its impact on the clinical outcome of Crohn's disease. See comment in PubMed Commons below J Crohns Colitis. 2012; 6: 674-680.
  • Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P,Walker S. Development of dominant bile duct stenosesin patientswith primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36:151–6.
  • Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814
  • Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464–72.
  • Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009; 39: 865-873
  • Kaplan MM: Primary biliary cirrhosis. The New England journal of medicine 1996, 335(21):1570-1580.
  • Ashraf I, Choudhary A, Arif M, Matteson ML, Hammad HT, Puli SR, Bechtold ML. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. Indian J Gastroenterol 2012; 31: 69-74